Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Zinforo®: High clinical cure rate and evidence of rapid response in CAP
Clinical cure rates: FOCUS 1 and 2
FOCUS 1 and 2 trials: Two Phase III, randomised, double-blind, multinational, multicentre, non-inferiority trials comparing Zinforo (600 mg IV every 12 hours, adjusted for moderate renal impairment) vs ceftriaxone (1 g IV every 24 hours)2
Zinforo has proven efficacy in CAP patients…
Clinical cure rates: FOCUS 1 and 2||
… and high early clinical response rates at Day 4, including for Streptococcus pneumoniae infections.3‡
Zinforo delivers high cure rates in patients with severe disease, risk factors for difficult-to-treat infections and a number of comorbidities2
Explore More
Read several CAP patient profiles describing potential scenarios where Zinforo could be a treatment of choice.
To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study.
||The lower limit of the 95% CI was above –10%, which met the predefined criteria for non-inferiority.7 Zinforo was well tolerated with a safety profile similar to that of ceftriaxone.7
‡Zinforo may be associated with early clinical response, based on clinical stability and symptom improvement criteria. Early clinical response does not predict final clinical outcome for Zinforo.
*CrCL 31–50 mL/min.2
† Shown not to be statistically significant.3
§ Bacteraemia was present in 4% of patients when baseline medical characteristics were assessed.2
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; FOCUS, CeFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalised patients; MITTE, modified intent-to-treat efficacy; PORT, Pneumonia Patient Outcomes Research Team. NS, non significant
Prescribing Information
Zinforo 600 mg powder for concentrate for solution for infusion
- ZINFORO. Summary of Product Characteristics
- File TM, et al. Clin Infect Dis 2010;51:1395–405
- Eckburg P, et al. Infect Dis Clin Pract 2012;51:1395–405
- Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
- Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
- Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
- Korczowski B et al, Paediatr Inf Dis J 2016 35 e239-47
Tolerability profile of Zinforo
Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials
** This is an optional area where footnotes can live.
Explore the outcomes of the other Zinforo Phase III clinical trials in patients with CAP and cSSTI
Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI**1,4-6
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020
No